Article: In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis

Cefpodoxime proxetil (U-76,252; CS-807) is a new esterified oral cephem antibiotic with a broad antibacterial spectrum. Since data regarding the activity of cefpodoxime against Branhamella catarrhalis are limited, we tested its activity against 200 B. catarrhalis isolates. The drug was highly active against beta-lactamase-negative and -positive isolates; 99% of all strains tested showed a cefpodoxime proxetil MIC of less than or equal to 2.0 micrograms/ml.

Citing Articles

Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis.

Verghese A, Roberson D, Kalbfleisch J, Sarubbi F Antimicrob Agents Chemother. 1990; 34(6):1041-4.

PMID: 2118322 PMC: 171754. DOI: 10.1128/AAC.34.6.1041.

Cefpodoxime proxetil concentrations in head and neck tissues.

Theopold H, Matthias C, Adam D Infection. 1991; 19(1):41-3.

PMID: 2013507 DOI: 10.1007/BF01643757.

In vitro activity of cefpodoxime against bacterial isolates obtained from patients with cancer.

Rolston K, Messer M, Nguyen H, Ho D, LeBlanc B, Bodey G Eur J Clin Microbiol Infect Dis. 1991; 10(7):581-5.

PMID: 1915401 DOI: 10.1007/BF01967278.

Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.

Knothe H, Shah P, Eckardt O Infection. 1991; 19(5):370-6.

PMID: 1800379 DOI: 10.1007/BF01645371.

Microbiological evaluation of cefpodoxime proxetil.

Wiedemann B, Luhmer E, Zuhlsdorf M Drugs. 1991; 42 Suppl 3:6-12.

PMID: 1726210 DOI: 10.2165/00003495-199100423-00004.

References

1.

Doern G, Morse S . Branhamella (Neisseria) catarrhalis: criteria for laboratory identification. J Clin Microbiol. 1980; 11(2):193-5. PMC: 273353. DOI: 10.1128/jcm.11.2.193-195.1980. View

2.

Yogev R, Melick C, Kabat W . In vitro and in vivo synergism between amoxicillin and clavulanic acid against ampicillin-resistant Haemophilus influenzae type b. Antimicrob Agents Chemother. 1981; 19(6):993-6. PMC: 181597. DOI: 10.1128/AAC.19.6.993. View

3.

Farmer T, Reading C . beta-Lactamases of Branhamella catarrhalis and their inhibition by clavulanic acid. Antimicrob Agents Chemother. 1982; 21(3):506-8. PMC: 181924. DOI: 10.1128/AAC.21.3.506. View

4.

Sweeney K, Verghese A, Needham C . In vitro susceptibilities of isolates from patients with Branhamella catarrhalis pneumonia compared with those of colonizing strains. Antimicrob Agents Chemother. 1985; 27(4):499-502. PMC: 180083. DOI: 10.1128/AAC.27.4.499. View

5.

Alvarez S, Jones M, Guarderas J, Berk S . In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis. Antimicrob Agents Chemother. 1985; 27(4):646-7. PMC: 180113. DOI: 10.1128/AAC.27.4.646. View

6.

Chin N, Neu H . In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746. Antimicrob Agents Chemother. 1988; 32(5):671-7. PMC: 172250. DOI: 10.1128/AAC.32.5.671. View

7.

Hager H, Verghese A, Alvarez S, Berk S . Branhamella catarrhalis respiratory infections. Rev Infect Dis. 1987; 9(6):1140-9. DOI: 10.1093/clinids/9.6.1140. View

8.

Doern G, Tubert T . In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods. Antimicrob Agents Chemother. 1988; 32(2):259-61. PMC: 172147. DOI: 10.1128/AAC.32.2.259. View

9.

Barry A, Jones R . Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests. J Clin Microbiol. 1988; 26(4):750-4. PMC: 266439. DOI: 10.1128/jcm.26.4.750-754.1988. View

10.

Jones R, Barry A . Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807). Antimicrob Agents Chemother. 1988; 32(4):443-9. PMC: 172198. DOI: 10.1128/AAC.32.4.443. View

11.

Utsui Y, Inoue M, Mitsuhashi S . In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Antimicrob Agents Chemother. 1987; 31(7):1085-92. PMC: 174876. DOI: 10.1128/AAC.31.7.1085. View

In Vitro Activity of Cefpodoxime Proxetil (U-76,252; CS-807) Against Clinical Isolates of Branhamella Catarrhalis